(Source: Opexa Therapeutics Inc) THE WOODLANDS, Texas--(BUSINESS WIRE)-- Opexa Therapeutics, Inc.(NASDAQ: OPXA), a biopharmaceutical company developing personalized otherapies for autoimmune disorders including multiple sclerosis (MS) and neuromyelitis optica (NMO), today announced results of a preclinical study, which show that T-cell immunotherapy with attenuated antigen-specific T-cells suppress the T-cell response to Aquaporin-4 (AQP4) in a dose-dependent manner, compared to vehicle control, as measured by reduction in both Aquaporin-4 reactive T-cell (ARTC) proliferation and associated cytokine activity. The results were statistically significant. In NMO, activated T-cells (ARTC) mount...
↧
